Ozlem Tureci

Summary

Publications

  1. doi request reprint Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals
    Ozlem Tureci
    Ganymed Pharmaceuticals AG, Freiligrathstr Mainz, Germany
    Gene 481:83-92. 2011
  2. doi request reprint In silico strategy for detection of target candidates for antibody therapy of solid tumors
    Gerd Helftenbein
    Ganymed Pharmaceuticals AG, Mainz, Germany
    Gene 414:76-84. 2008
  3. doi request reprint Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms
    Stefan Wöll
    Ganymed Pharmaceuticals AG, Mainz, Germany
    Int J Cancer 134:731-9. 2014

Collaborators

Detail Information

Publications3

  1. doi request reprint Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals
    Ozlem Tureci
    Ganymed Pharmaceuticals AG, Freiligrathstr Mainz, Germany
    Gene 481:83-92. 2011
    ..Given that CLDN18.2 is a novel drug target candidate, our data is also relevant for drug development as it reveals all six investigated mammalian species as suitable models for testing safety of CLDN18.2 targeting regimen...
  2. doi request reprint In silico strategy for detection of target candidates for antibody therapy of solid tumors
    Gerd Helftenbein
    Ganymed Pharmaceuticals AG, Mainz, Germany
    Gene 414:76-84. 2008
    ..The impact of such stringent input control on accuracy of prediction is underlined by RT-PCR confirmation of predicted tissue distribution patterns for a number of selected candidates...
  3. doi request reprint Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms
    Stefan Wöll
    Ganymed Pharmaceuticals AG, Mainz, Germany
    Int J Cancer 134:731-9. 2014
    ..Thus, a considerable number of patients with pancreatic neoplasms would be in principle eligible for a CLDN18.2-targeting approach...